Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673049 · ClinicalTrials.gov registry record · Phase 3
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
NCT00673049: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00673049 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 583 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00673049, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
Study Summary
The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).
Primary Outcome
The time from date of randomization to date of death due to any cause. For participants who were alive, overall survival was censored at the last contact.
Interventions
- DRUG Erlotinib
- DRUG CP 751,871 (Figitumumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Why NCT00673049 stopped before completion
NCT00673049 is an interventional study that assigns participants to a tested intervention. The registered 583 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00673049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00673049 about?
NCT00673049 is a clinical study titled "Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer". The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).
What is the current status of trial NCT00673049?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 2008-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00673049?
The interventions under investigation include: Erlotinib (DRUG), CP 751,871 (Figitumumab) (DRUG).
Who is sponsoring clinical trial NCT00673049?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00673049's enrollment target sits among peer trials
583 652nd of 2000 higher than 1,348 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
- NCT04984291 · 584 participants · NA
Zimmer Biomet Shoulder Arthroplasty PMCF
- NCT05983757 · 584 participants · NA
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
- NCT06569290 · 584 participants · NA
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia